Experimental combo targets Hard-to-Treat lymphoma
NCT ID NCT05896163
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two experimental drugs, maplirpacept and glofitamab, given after a single dose of obinutuzumab, in adults with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatments. Participants had already tried at least two standard therapies and could not or would not have a stem cell transplant. The goal was to find a safe and effective dose of the combination. However, the trial was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
maplirpacept (PF-07901801) combined with glofitamab and obinutuzumab
What this could lead to
If it works, this could offer a new treatment option for people with DLBCL who have run out of standard therapies and cannot have a stem cell transplant.
What could go wrong
This trial was terminated early, so results may be limited. It is also an early-phase study (Phase 1b/2) with a small number of participants, so safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barnes-Jewish Hospital Parkview Tower
St Louis, Missouri, 63110, United States
-
Gazi University I lcalth Research and Annlica1ion Cenlcr Gazi Hospilal
Ankara, 06560, Turkey (Türkiye)
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
-
Rambam Health Care Campus
Haifa, Northern District, 3109601, Israel
-
Sheba Medical Center
Ramat Gan, Central District, 5262100, Israel
-
Shizuoka Cancer Center
Nagaizumi-cho, Shizuoka, 411-8777, Japan
-
Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Sourasky Medical Center
Tel Aviv, TELL ABĪB, 6423906, Israel
-
University of Kansas Hospital Cambridge North Tower A
Kansas City, Kansas, 66160, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States